Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| FG Communities Holdings Inc.FGF · Entity 7310 | CFO | August 04, 2025 | August 08, 2025 |
| Sonnet BioTherapeutics Holdings, Inc.HOTR · Entity 72220 | Chief Operating Officer | December 28, 2016 | December 28, 2016 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
FG Communities Holdings Inc.
Report date August 04, 2025 · Filed August 08, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Pre - Funded Common Stock Purchase WarrantSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,000 |
Reported balance
After 2025-08-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2025-08-04 · Grant · Acquired 30,000 · Balance 30,000 F1: Exercise subject to the latter of the (i) effectiveness of articles of amendment to the Company's amended and restated articles of incorporation to increase authorized shares to 1,000,000,000 and (ii) 21st day following final information statement for Nasdaq Rule 5635(d) approval (the "Initial Exercise Date"). F2: No expiration until exercised in full; exercise price pre-funded |
| Common StockSEC Table I · non-derivative | Direct | 12,083 |
Reported balance
Holding disclosure · report date 2025-08-04 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 12,083 |
Filing footnotes · ownership attribution and instrument terms
F1: Exercise subject to the latter of the (i) effectiveness of articles of amendment to the Company's amended and restated articles of incorporation to increase authorized shares to 1,000,000,000 and (ii) 21st day following final information statement for Nasdaq Rule 5635(d) approval (the "Initial Exercise Date").
F2: No expiration until exercised in full; exercise price pre-funded
Sonnet BioTherapeutics Holdings, Inc.
Report date December 28, 2016 · Filed December 28, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Series 1 Preferred StockSEC Table I · non-derivative | Direct | 100 |
Reported balance
After 2016-12-28 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2016-12-28 · Purchase · Acquired 100 · Balance 100 F1: This Series 1 Preferred Stock was purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant. F3: This purchase price is for the total number of units purchased. |
| Series 1 WarrantsSEC Table II · derivative / convertible security · Conversion / exercise price $13.50 | Direct | 100 |
Reported balance
After 2016-12-28 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2016-12-28 · Grant · Acquired 100 · Balance 100 F2: These Series 1 Warrants were purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant. F7: The price is paid by surrendering one share of Series 1 Preferred stock. F3: This purchase price is for the total number of units purchased. F4: These warrants are exercisable at any time at any time and from time to time on or before the seventh anniversary of the date of issuance. F5: These warrants expire in accordance with their terms and no later than on the seventh anniversary of their issue date. F6: Each Series 1 Warrant is exercisable into 10 shares of common stock. |
| Common StockSEC Table I · non-derivative | Direct | 16,663 |
Reported balance
Holding disclosure · report date 2016-12-28 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 16,663 |
Filing footnotes · ownership attribution and instrument terms
F1: This Series 1 Preferred Stock was purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant.
F2: These Series 1 Warrants were purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant.
F3: This purchase price is for the total number of units purchased.
F4: These warrants are exercisable at any time at any time and from time to time on or before the seventh anniversary of the date of issuance.
F5: These warrants expire in accordance with their terms and no later than on the seventh anniversary of their issue date.
F6: Each Series 1 Warrant is exercisable into 10 shares of common stock.
F7: The price is paid by surrendering one share of Series 1 Preferred stock.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
CYNERGISTEK, INC
Report date September 01, 2022 · Filed September 01, 2022
Section 16 reporting ended · disclosed 2022-09-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2022-09-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2022-09-01 · Grant · Acquired 25,000 · Balance 96,000 F1: Represents accelerated vesting and settlement of restricted stock units (RSUs) pursuant to the Merger Agreement (as defined below). Row 2 · 2022-09-01 · Disposition to issuer · Disposed 96,000 · Balance 0 F2: Disposed of pursuant to an Agreement and Plan of Merger, dated as of May 23, 2022 (the "Merger Agreement") by and among the Issuer, Clearwater Compliance LLC, a Tennessee limited liability company (the "Parent"), and Clearwater Compliance Acquisition Company I, a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. Each share of common stock exchanged in the Merger will receive cash of $1.25 per share. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.55 · Expires 2026-06-06 | Direct | 0 |
Reported balance
After 2022-09-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2022-09-01 · Disposition to issuer · Disposed 8,334 · Balance 0 F3: Pursuant to the terms of the Merger Agreement, this option, which fully vested on June 6, 2019, was canceled for no consideration at the effective time of the Merger because its exercise price exceeded the per share merger consideration of $1.25 per share. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents accelerated vesting and settlement of restricted stock units (RSUs) pursuant to the Merger Agreement (as defined below).
F2: Disposed of pursuant to an Agreement and Plan of Merger, dated as of May 23, 2022 (the "Merger Agreement") by and among the Issuer, Clearwater Compliance LLC, a Tennessee limited liability company (the "Parent"), and Clearwater Compliance Acquisition Company I, a Delaware corporation and a wholly owned subsidiary of the Parent (the "Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), with the Issuer surviving the Merger as a wholly-owned subsidiary of Parent. Each share of common stock exchanged in the Merger will receive cash of $1.25 per share.
F3: Pursuant to the terms of the Merger Agreement, this option, which fully vested on June 6, 2019, was canceled for no consideration at the effective time of the Merger because its exercise price exceeded the per share merger consideration of $1.25 per share.
FG Group Holdings Inc.
Report date February 29, 2024 · Filed March 01, 2024
Section 16 reporting ended · disclosed 2024-03-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-29 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2024-02-29 · Disposition to issuer · Disposed 145,613 · Balance 0 F1: On January 3, 2024, Fundamental Global Inc. (f/k/a FG Financial Group, Inc., the "Parent"), FG Group LLC (the "Acquiror"), and FG Group Holdings Inc. (the "Company") entered into a Plan of Merger (the "Merger Agreement"), pursuant to which the Company merged with and into the Acquiror, with the Acquiror surviving the merger as a wholly owned subsidiary of the Parent (the "Merger"). On February 29, 2024, at approximately 4:05 PM Eastern time, the effective time of the Merger (the "Effective Time"), all of the outstanding shares of common stock of the Company ("Company Common Stock") were converted into shares of common stock of the Parent ("Parent Common Stock") on a 1:1 basis (the "Exchange Ratio") pursuant to the terms of the Merger Agreement. F2: Disposed of pursuant to the Merger Agreement in exchange for a number of shares of Parent Common Stock equal to the product of (i) the number of shares of Company Common Stock owned as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-02-29 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2024-02-29 · Disposition to issuer · Disposed 80,000 · Balance 0 F1: On January 3, 2024, Fundamental Global Inc. (f/k/a FG Financial Group, Inc., the "Parent"), FG Group LLC (the "Acquiror"), and FG Group Holdings Inc. (the "Company") entered into a Plan of Merger (the "Merger Agreement"), pursuant to which the Company merged with and into the Acquiror, with the Acquiror surviving the merger as a wholly owned subsidiary of the Parent (the "Merger"). On February 29, 2024, at approximately 4:05 PM Eastern time, the effective time of the Merger (the "Effective Time"), all of the outstanding shares of common stock of the Company ("Company Common Stock") were converted into shares of common stock of the Parent ("Parent Common Stock") on a 1:1 basis (the "Exchange Ratio") pursuant to the terms of the Merger Agreement. F3: Restricted Share Units (RSUs) granted as non-employee director compensation pursuant to the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. Each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms, as were applicable to such Company RSU immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.25 · Expires 2028-12-04 | Direct | 0 |
Reported balance
After 2024-02-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-29 · Disposition to issuer · Disposed 40,000 · Balance 0 F4: Stock Options granted under the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each Stock Option to purchase shares of Company Common Stock (a "Company Stock Option") that was outstanding immediately prior to the Effective Time, was converted into a stock option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Stock Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. F5: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, December 4, 2018, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.89 · Expires 2029-06-06 | Direct | 0 |
Reported balance
After 2024-02-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-02-29 · Disposition to issuer · Disposed 30,000 · Balance 0 F4: Stock Options granted under the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each Stock Option to purchase shares of Company Common Stock (a "Company Stock Option") that was outstanding immediately prior to the Effective Time, was converted into a stock option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Stock Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. F6: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, June 6, 2019, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.60 · Expires 2030-10-09 | Direct | 0 |
Reported balance
After 2024-02-29 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2024-02-29 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: Stock Options granted under the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each Stock Option to purchase shares of Company Common Stock (a "Company Stock Option") that was outstanding immediately prior to the Effective Time, was converted into a stock option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Stock Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. F7: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, October 9, 2020, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: On January 3, 2024, Fundamental Global Inc. (f/k/a FG Financial Group, Inc., the "Parent"), FG Group LLC (the "Acquiror"), and FG Group Holdings Inc. (the "Company") entered into a Plan of Merger (the "Merger Agreement"), pursuant to which the Company merged with and into the Acquiror, with the Acquiror surviving the merger as a wholly owned subsidiary of the Parent (the "Merger"). On February 29, 2024, at approximately 4:05 PM Eastern time, the effective time of the Merger (the "Effective Time"), all of the outstanding shares of common stock of the Company ("Company Common Stock") were converted into shares of common stock of the Parent ("Parent Common Stock") on a 1:1 basis (the "Exchange Ratio") pursuant to the terms of the Merger Agreement.
F2: Disposed of pursuant to the Merger Agreement in exchange for a number of shares of Parent Common Stock equal to the product of (i) the number of shares of Company Common Stock owned as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio.
F3: Restricted Share Units (RSUs) granted as non-employee director compensation pursuant to the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each RSU convertible into shares of Company Common Stock (a "Company RSU") that was outstanding immediately prior to the Effective Time, was converted into an RSU to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company RSU as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio. Each assumed Company RSU will continue to be governed by the same terms and conditions, including vesting terms, as were applicable to such Company RSU immediately prior to the Effective Time.
F4: Stock Options granted under the FG Group Holdings, Inc. 2017 Omnibus Equity Compensation Plan. Pursuant to the Merger Agreement, each Stock Option to purchase shares of Company Common Stock (a "Company Stock Option") that was outstanding immediately prior to the Effective Time, was converted into a stock option to acquire the number of shares of Parent Common Stock equal to the product of (i) the number of shares subject to such Company Stock Option as of immediately prior to the Effective Time, multiplied by (ii) the Exchange Ratio.
F5: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, December 4, 2018, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time.
F6: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, June 6, 2019, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time.
F7: This Company Stock Option, which provided for vesting in five equal annual installments on the first anniversary of the grant date, October 9, 2020, was assumed in the Merger and will continue to be governed by the same terms and conditions, including vesting terms and exercise price, as were applicable to such Company Stock Option immediately prior to the Effective Time.
Strong Global Entertainment, Inc.
Report date September 30, 2024 · Filed October 02, 2024
Section 16 reporting ended · disclosed 2024-10-02. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common Voting SharesSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2024-09-30 transaction · row 1
1 source rowRow 1 · 2024-09-30 · Other · Disposed 20,950 · Balance 0 F1: On September 30, 2024, in connection with the business combination of Strong Global Entertainment, Inc. ("SGE") with and into Fundamental Global Inc., ("FG"), each share of Class A Common Voting Stock of SGE was exchanged for 1.5 shares of FG common stock. SGE will terminate its status as a reporting company following the closing of the combination. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2024-09-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-09-30 · Other · Disposed 20,000 · Balance 0 F2: These Restricted Stock Units ("RSU") were granted on May 18, 2023 and 10,000 will vest on the second anniversary of the grant date, and 10,000 will vest on the third anniversary of the grant date. On September 30, 2024, in connection with the business combination. the RSUs were exchanged for FG RSUs on a 1:1.5 basis. |
Filing footnotes · ownership attribution and instrument terms
F1: On September 30, 2024, in connection with the business combination of Strong Global Entertainment, Inc. ("SGE") with and into Fundamental Global Inc., ("FG"), each share of Class A Common Voting Stock of SGE was exchanged for 1.5 shares of FG common stock. SGE will terminate its status as a reporting company following the closing of the combination.
F2: These Restricted Stock Units ("RSU") were granted on May 18, 2023 and 10,000 will vest on the second anniversary of the grant date, and 10,000 will vest on the third anniversary of the grant date. On September 30, 2024, in connection with the business combination. the RSUs were exchanged for FG RSUs on a 1:1.5 basis.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 28, 2016 Filed Dec 28, 2016 18:39 UTC | Sonnet BioTherapeutics Holdings, Inc. HOTR · Entity 72220 | GrantSeries 1 Warrants · Derivative | 100 | $13.50 Strike: $13.50 | $1,350.00 |
DisclosureSEC source: 0001493152-16-016225 · form4.xml · derivative · entry 3 Roberson Mark Daniel · CIK 0001415593 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 Underlying: Common Stock · 1,000 shares Expires not disclosed F2 · security: These Series 1 Warrants were purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant. F7 · derivative.exercise_price: The price is paid by surrendering one share of Series 1 Preferred stock. F3 · price: This purchase price is for the total number of units purchased. F4 · derivative.exercise_date: These warrants are exercisable at any time at any time and from time to time on or before the seventh anniversary of the date of issuance. F5 · derivative.expiration_date: These warrants expire in accordance with their terms and no later than on the seventh anniversary of their issue date. F6 · derivative.underlying_shares: Each Series 1 Warrant is exercisable into 10 shares of common stock. Read SEC document |
| December 28, 2016 Filed Dec 28, 2016 18:39 UTC | Sonnet BioTherapeutics Holdings, Inc. HOTR · Entity 72220 | PurchaseSeries 1 Preferred Stock | 100 | $13.50 | $1,350.00 |
DisclosureSEC source: 0001493152-16-016225 · form4.xml · nonDerivative · entry 2 Roberson Mark Daniel · CIK 0001415593 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100 F1 · security: This Series 1 Preferred Stock was purchased as part of a rights offering to purchase units, each consisting of one Series 1 Preferred Share and one Series 1 Warrant. F3 · price: This purchase price is for the total number of units purchased. Read SEC document |
| December 20, 2016 Filed Dec 20, 2016 21:54 UTC | Sonnet BioTherapeutics Holdings, Inc. HOTR · Entity 72220 | PurchaseCommon Stock | 2,000 | $0.43 | $860.00 |
DisclosureSEC source: 0001493152-16-016062 · form4.xml · nonDerivative · entry 1 Roberson Mark Daniel · CIK 0001415593 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,663 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.